Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

Abstract Number: 2367 • ACR Convergence 2025
Real-World Effectiveness of Risankizumab on Axial Symptoms in Biologic-Naïve Patients With Psoriatic Arthritis in the United States and Europe
Philip J. Mease¹, Andrew Ostor², Christopher Saffore³, Xiaolan Ye⁴, Manish Patel⁵, Ana Biljan⁶, Ralph Lippe⁵, Molly Edwards⁷, Iwan Armstrong⁷ and Xenofon Baraliakos⁸, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Australian National University, Canberra, Australia, ³AbbVie Inc., waukegan, IL, ⁴AbbVie Inc., Mettawa, IL, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Inc., Buffalo Grove, IL, ⁷Adelphi Real World, Bollington, United Kingdom, ⁸Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Axial involvement is a clinically relevant manifestation of psoriatic arthritis (PsA) that can influence management strategies. Evidence on the real-world effectiveness of advanced therapies,…
Abstract Number: 2039 • ACR Convergence 2025
To Hold or Not to Hold: Variability in Management of DMARDs in the Setting of Acute Infections – A Survey of Rheumatologists
Mollie Gellman¹, Medhasweta Sen², Ari Schwartz³, Peter Merkel⁴ and Nadine Mbuyi⁵, ¹Montefiore Medical Center, Bronx, NY, ²University of Virginia, Charlottesville, VA, ³Rheumatology Consultants PC, Brockton, MA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵George Washington University, Washington, DC
Background/Purpose: Disease-modifying antirheumatic drugs (DMARDs) vary widely in their immunosuppressive activity. Guidance on managing DMARDs during acute infections is limited, particularly regarding when to hold…
Abstract Number: 1453 • ACR Convergence 2025
Real-World Comparative Effectiveness of Upadacitinib in Psoriatic Arthritis: Evaluation of Switching to Upadacitinib Versus Tumor Necrosis Factor Inhibitors or Interleukin-17 Inhibitors After First-Line Tumor Necrosis Factor Inhibitors
Philip J. Mease¹, William Tillett², Xiaolan Ye³, Christopher Saffore⁴, Molly Edwards⁵, Isabel Truman⁵, Sophie Barlow⁶, Jayne Stigler⁷, Bhumik Parikh⁸ and Daniel Aletaha⁹, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, ³AbbVie Inc., Mettawa, IL, ⁴AbbVie Inc., waukegan, IL, ⁵Adelphi Real World, Bollington, United Kingdom, ⁶AbbVie, North Chicago, IL, ⁷AbbVie, Round Lake, IL, ⁸AbbVie, Hillsborough Township, NJ, ⁹Medical University Vienna, Wien, Austria
Background/Purpose: The aim of this study was to compare the effectiveness of switching from a first-line TNFi to upadacitinib (UPA), an oral JAKi, versus cycling…
Abstract Number: 1274 • ACR Convergence 2025
Analysis of Vaccination Compliance In Patients With Juvenile Idiopathic Arthritis At The Rheumatology Transitional Consultation
Andres Perez Hurtado¹, Jose Ivorra Cortes², ELENA GRAU GARCIA³, Miguel Simeo Vinaixa⁴, Iago Alcantara Alvarez⁴, Belen Villanueva Manes⁵, Alba Maria Torrat Noves⁶, Daniel Ramos Castro⁷, Pablo Muñoz Martinez⁴, Laura mas sanchez⁸, Berta López Montesinos⁹, Lucía Lacruz Pérez¹⁰ and José Andrés Román Ivorra¹¹, ¹Hospital Universitario y Politècnico La Fe, València, Comunidad Valenciana, Spain, ²Hospital Universitario La Fe, Valencia, Comunidad Valenciana, Spain, ³HUP La Fe, Valencia, Comunidad Valenciana, Spain, ⁴Rheumatology Department. HUP La Fe, Valencia, Spain, ⁵Hospital La Fe, València, Spain, ⁶Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain, ⁷Hospital Universitari i Politecnic La Fe, Valencia, Spain, ⁸Hospital Universitario y Politécnico La Fe, Valencia, Comunidad Valenciana, Spain, ⁹Pediatric Rheumatology Department. HUP La Fe, Valencia, Spain, ¹⁰Pediatric Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ¹¹Hospital Universitari i Politècnic La Fe, Valencia, Spain
Background/Purpose: Juvenile idiopathic arthritis is the most common group of inflammatory rheumatic diseases in childhood. Its early onset and the immunosuppressive treatments used to control…
Abstract Number: 0662 • ACR Convergence 2025
Efficacy Across Baseline Characteristic Subgroups in Patients With Systemic Lupus Erythematosus Treated With Upadacitinib: Results From SLEek, a Phase 2 Randomized
Marta Mosca¹, Karen H. Costenbader², Amit Saxena³, Michelle Petri⁴, Andrea Rubbert-Roth⁵, Karim Masri⁶, Christopher Saffore⁷, Ling Cheng⁸ and Joan Merrill⁹, ¹University of Pisa, Pisa, Pisa, Italy, ²Harvard Medical School and Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ⁴Johns Hopkins University School of Medicine, Timonium, MD, ⁵Division of Rheumatology and Immunology, Cantonal Hospital St Gallen, St Gallen, Switzerland, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Inc., waukegan, IL, ⁸AbbVie, North, IL, ⁹Oklahoma Medical Research Foundation, Oklahoma City ⁷³¹⁰⁴, OK
Background/Purpose: Clinical and immunological manifestations of systemic lupus erythematosus (SLE) vary widely across patients, complicating diagnosis and treatment (1,2). Upadacitinib (UPA), an oral selective JAK…
Abstract Number: 0751 • ACR Convergence 2025
Impact of Treatment with Upadacitinib on Biomarkers Identified by Proteomics in Giant Cell Arteritis
Lisa Christ¹, Shalina Taylor², Yilin Xu², Rhiya Sharma², Thierry Sornasse², Yingtao Bi², Heath Guay², Arathi Setty³, Ana Romero⁴, Peter Merkel⁵, Eugenio de Miguel⁶, Christian Dejaco⁷ and Cornelia Weyand⁸, ¹Department of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Bern, Switzerland, ²AbbVie Inc, North Chicago, ³AbbVie Inc, North Chicago, IL, ⁴AbbVie, Barcelona, Spain, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Hospital Universitario La Paz, Madrid, Spain, ⁷Medical University of Graz, Department of Rheumatology, Graz, Austria; Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, ⁸Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester
Background/Purpose: Interleukin-6 (IL-6) and interferon-gamma (IFNγ) have been identified as key drivers in the pathogenesis of giant cell arteritis (GCA), that promote disease progression. The…
Abstract Number: 0454 • ACR Convergence 2025
Models to predict flare and sustained remission in Rheumatoid Arthritis patients on optimization treatment with bDMARDs: clinical and molecular insights
Laura Galindo Domínguez¹, Belen Acasuso¹, Vanesa Balboa², Juan Cañete³, Benjamin Fernández-Gutiérrez⁴, Isidoro Gonzalez-Alvaro⁵, jose Luis Pablos⁶, Carmen Bejerano-Herreria⁷, Maite silva⁸, Ignacio rego Pérez⁹, Cristina Ruiz-Romero¹⁰, Francisco J De-Toro-Santos¹¹, Natividad Oreiro¹² and francisco J Blanco¹³, ¹Grupo de Investigación en Reumatología (GIR). INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC). SERGAS, A Coruña, Galicia, Spain, ²Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, coruña, Spain, ³Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, ⁴Department of Rheumatology and Health Research Institute (IdISSC), Hospital Clínico San Carlos, Madrid, Spain., Madrid, Madrid, Spain, ⁵Department of Rheumatology, Hospital Universitario La Princesa, IIS, Madrid Spain, Madrid, Spain, ⁶Department of Rheumatology, Instituto de Investigación Hospital ¹² de Octubre, Complutense University of Madrid, Madrid, Madrid, Spain, ⁷Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁸Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, A Coruña, Spain, A Coruña, Galicia, Spain, ⁹Department of Rheumatology, Rheumatology Research Group (GIR) Biomedical Re-search Institute (INIBIC), A Coruña, Spain, ¹⁰Department of Rheumatology, Rheumatology Research Group (GIR) Biomedical Re-search Institute (INIBIC),, A Coruña, Spain, ¹¹Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, A Coruña, Spain, A Coruña, ¹²CHUAC, La Coruna, Spain, ¹³INIBIC-University of A Coruña, A Coruña, Galicia, Spain
Background/Purpose: Optimization of biologic DMARDs (bDMARDs) in patients with rheumatoid arthritis (RA) may be feasible in those who have maintained remission for at least six…
Abstract Number: 2366 • ACR Convergence 2025
Association Between Skin and Joint Symptom Control and Patient-Reported Pain and Health Status Among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs
Philip J. Mease¹, Nicole Middaugh², Yolanda Muñoz Maldonado², Chao Song³, Skyler Peterson⁴, Robert Low³ and Alexis Ogdie⁵, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²CorEvitas, LLC, Waltham, MA, ³UCB, Smyrna, GA, ⁴CorEvitas, LLC, Waltham, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory condition primarily affecting the joints and skin.1 More severe symptoms are associated with lower health-related quality of…
Abstract Number: 2036 • ACR Convergence 2025
JAK1 selective inhibitors versus pan-JAK inhibitors: comparative real-world study of drug retention in chronic inflammatory arthritis
LETICIA LEON¹, Pedro Pablo Bermejo², Leonor Laredo³, José Alberto Peña⁴, María Teresa Benítez⁵, DALIFER FREITES⁶, CLARA DE MIGUEL³ and lydia Abasolo Alcazar⁷, ¹Fundación Investigación Biomédica Hospital Clínico San Carlos, IdISSC; Universidad Camilo Jose Cela, MADRID, Madrid, Spain, ²Clinical Pharmacology Service, San Carlos Clinical Hospital, MADRID, Madrid, Spain, ³Hospital Clinico San Carlos, MADRID, Madrid, Spain, ⁴Pharmacy Service San Carlos Clinical Hospital, MADRID, Madrid, Spain, ⁵San Carlos Clinical Hospital, MADRID, Madrid, Spain, ⁶Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, ⁷IdISSC. HCSC, Madrid, Madrid, Spain
Background/Purpose: Janus kinase inhibitors (JAKis) are effective therapeutic agents against chronic inflammatory arthritis (CIA). Tofacitinib and baricitinib were defined as pan-JAK inhibitors, while upadacitinib and…
Abstract Number: 1449 • ACR Convergence 2025
Bimekizumab Demonstrated Comparable One-Year Efficacy in Male and Female Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Lianne S. Gensler¹, Sofia Ramiro², Denis Poddubnyy³, Marina Magrey⁴, Irene E. van der Horst-Bruinsma⁵, Atul Deodhar⁶, Vanessa Taieb⁷, Diana Voiniciuc⁸, Natasha de Peyrecave⁹ and Martin Rudwaleit¹⁰, ¹Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²Leiden University Medical Center, Bunde, Netherlands, ³Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ⁴Case Western Reserve University School of Medicine/University Hospitals Cleveland, Richfield, OH, ⁵Department of Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ⁶Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁷UCB, Colombes, France, ⁸UCB, Slough, United Kingdom, ⁹UCB, Brussels, Belgium, ¹⁰Bielefeld University, Medical School and University Medical Centre OWL, Klinikum Bielefeld, Department of Rheumatology, Bielefeld, Germany
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. BKZ has shown sustained efficacy to Week (Wk) 52…
Abstract Number: 1182 • ACR Convergence 2025
Cardiac Sarcoidosis in Black Patients: A Biopsy-Confirmed Cohort Study
Roshan Subedi¹, Haya Haddad², Rachel Barish¹, Tania Vora¹, Nana Afari-Armah³, Ajay Kadakkal¹, Farooq Sheikh¹ and Florina Constantinescu¹, ¹Medstar Washington Hospital Center, Washington, DC, ²Medstar Washington Hospital Center, Silver Spring, MD, ³Medstar Washington Hospital Center, Washington
Background/Purpose: Sarcoidosis is an inflammatory disease characterized by non-necrotizing granulomatous inflammation that can affect any organ. Approximately 5% of patients with sarcoidosis develop clinically significant…
Abstract Number: 0592 • ACR Convergence 2025
An Interim Analysis of Health-Related Quality of Life Outcomes from an International Multicentre Observational Study in Patients with Axial Spondyloarthritis Initiating Bimekizumab in Real-World Clinical Practice
Xenofon Baraliakos¹, Uta Kiltz¹, Kurt de Vlam², Adeline Ruyssen-Witrand³, Julio Ramírez Garcia⁴, Jessica A. Walsh⁵, Denis Poddubnyy⁶, David Nicholls⁷, Marga Oortgiesen⁸, Francesca Maria Ester Castagna⁹, Marie-Alix Bonny¹⁰, Hervé Besson¹¹, Rajan Bajracharya¹², Patrik Öhagen¹³, Christine de La Loge¹⁰ and William Tillett¹⁴, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²Department of Rheumatology, UZ Leuven, Leuven, Belgium, ³CHU of Toulouse - Pierre-Paul Riquet Hospital (Inflammation, Infection, Immunology and Locomotor Center - Rheumatology Service, Toulouse, France, ⁴Rheumatology Department, Hospital Clinic and IDIBAPS of Barcelona, Barcelona, Spain, ⁵Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁶Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ⁷Clinical Trials Unit, University of the Sunshine Coast, Queensland, Australia, ⁸UCB, Raleigh, NC, ⁹UCB SpA, Milano, Italy, ¹⁰UCB, Brussels, Belgium, ¹¹UCB, Breda, Netherlands, ¹²UCB, Slough, England, United Kingdom, ¹³UCB, Stockholm, Sweden, ¹⁴Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease with a significant burden on patients’ (pts) health-related quality of life (HRQoL).1 Bimekizumab (BKZ), a monoclonal…
Abstract Number: 0731 • ACR Convergence 2025
The Efficacy of Leflunomide in the Treatment of Giant Cell Arteritis: A Systematic Review and Meta-Analysis
Linda Zhu¹, Arielle Mendel², Carolyn Ross³ and Jean-Paul Makhzoum¹, ¹Universite de Montreal, Montreal, Canada, ²McGill University Health Centre, Montréal, QC, Canada, ³University of Montreal, Longueuil, Canada
Background/Purpose: The objective of this systematic review is to assess the effectiveness of leflunomide in the treatment of new-onset, refractory or relapsing giant cell arteritis…
Abstract Number: 0453 • ACR Convergence 2025
Safety of DMARDs in Rheumatoid Arthritis: A Nationwide Study of ILD Risk and Outcomes in RA-ILD
kyung-Ann Lee¹, Bora Lee², Hyun-Sook Kim³ and Se Hee Kim⁴, ¹Soonchunhyang University Hospital Seoul: Soonchunhyang University Hospital, Seoul, Republic of Korea, ²Chosun University, GwangJu, Republic of Korea, ³Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea, ⁴Kyung Hee University College of Medicine, Seoul, Republic of Korea
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a potentially life-threatening extra-articular manifestation of RA. The comparative safety of disease-modifying antirheumatic drugs (DMARDs) in RA…
Abstract Number: 2351 • ACR Convergence 2025
Modulation of Tyrosine Kinase 2- and Disease-Related Biomarkers by Zasocitinib (TAK-279), an Oral, Allosteric, Highly Selective and Potent Tyrosine Kinase 2 Inhibitor, Is Associated With Clinical Response in Patients with Active Psoriatic Arthritis
Amit Choudhury¹, Jie Cheng², Feng Hong¹, Sachin Kumar¹, Jay Tang¹, Paresh Thakker¹, Banishree Saha¹, Vinayagam Arunachalam³, Ting Hong³, Elena Tomaselli Muensterman¹, Haakan Wennbo³ and Iain McInnes⁴, ¹Takeda Development Center Americas, Inc.,, Cambridge, MA, ²Takeda Development Center Americas, Inc., Cambridge, MA, ³Takeda Development Center Americas, Inc, Cambridge, MA, ⁴University of Glasgow, Glasgow, United Kingdom
Background/Purpose: There is a significant unmet need for clinically informative biomarkers of disease activity and therapeutic response in immune-mediated inflammatory diseases (IMIDs). Tyrosine kinase 2…

1
2
3
…
48
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].